Chris Neary joined NanoCellect as CEO in 2018. With over 30 years of experience leading commercialization of life sciences solutions to advance automated drug discovery with Sagian, a company acquired by Beckman Coulter in 1996. Chris advanced to senior management roles at Beckman Coulter; initially leading the growth of Beckman’s automation solutions, genomic sequencing, and tools businesses and then promoted to leading Corporate Strategy for Beckman in 2009. After the acquisition by Danaher in 2011, Chris transitioned to Beckman Coulter Life Sciences assuming leadership of product management and strategy that included Beckman’s cellular analysis business. Chris was approached by the Private Equity firm, Water Street, to assume the leadership of AROTEC Diagnostics, a New Zealand antigen diagnostics company, growing this business by 300% in three years that resulted in the acquisition of this business to Sebia Diagnostics. Given his proven track record of executing growth of life sciences portfolios, and M&A leadership at both Beckman and Danaher, he joined NanoCellect to further advance our growth strategy. With the founders of NanoCellect, Chris drove our execution to enable NanoCellect to lead our differentiated leadership in microfluidic cell sorting solutions that has enabled our customers’ ability to advance their research efforts in cellular discoveries.